Lilly has another candidate further ahead in development outside China that is taking up more of its R&D investment, namely retatrutide, a triple-acting agent that targets GLP-1, GIP, and glucagon in one molecule and is in several phase 3 trials across weight loss, diabetes, obstructive sleep apnoea, osteoarthritis, and chronic lower back pain, as well as for reducing the risk of cardiovascular and kidney complications in people with obesity
Is there evidence that medication-related anxiety resolves when the medication is adjusted or discontinued
HPLC analysis provides a chromatographic purity profile that identifies both the target peptide peak and any impurity peaks their ratio determines the reported purity percentage
Yes, especially with tinctures or infused oils
These medicines are prescribed alongside dietary changes, physical activity and long-term lifestyle support